📊 ANRO Key Takeaways
Is Alto Neuroscience, Inc. (ANRO) a Good Investment?
Alto Neuroscience is a pre-revenue pharmaceutical company with severe operational losses and negative free cash flow, indicating the business is in early clinical development with no commercial products generating revenue. Despite strong liquidity and balance sheet strength, the company is burning substantial cash (-$51.8M operating CF) with only 6.7 years of cash runway at current burn rates, creating significant going concern risk before reaching profitability.
Alto Neuroscience remains a pre-revenue biotech with substantial operating and net losses, negative operating cash flow, and no evidence yet of self-sustaining growth quality. Its balance sheet is a clear support, with $176.48M in cash, very low leverage, and strong liquidity, but the core fundamentals still depend on successful clinical execution rather than operating performance. Until revenue visibility or meaningful loss improvement emerges, the fundamentals skew weak despite solid near-term financial flexibility.
Why Buy Alto Neuroscience, Inc. Stock? ANRO Key Strengths
- Strong liquidity position with $176.5M cash equivalents and 15.69x current ratio
- Minimal debt burden with 0.11x debt-to-equity ratio providing financial flexibility
- Net loss improved 2.9% YoY indicating some operational progress
- Very strong liquidity, with a 15.69x current and quick ratio supported by $176.48M in cash
- Low balance-sheet leverage, with debt/equity of just 0.11x and equity of $151.14M
- Minimal capital expenditure needs, which helps preserve cash relative to many asset-heavy businesses
ANRO Stock Risks: Alto Neuroscience, Inc. Investment Risks
- Pre-revenue stage with no commercial products; entirely dependent on clinical trial success and regulatory approval
- Substantial cash burn of $51.8M annually from operations will exhaust capital within ~6-7 years without revenue generation
- Negative returns on equity (-41.8%) and assets (-34.2%) demonstrate value destruction; typical for biotech but reflects execution risk
- Diluted EPS of -$2.19 indicates significant shareholder dilution through financing activities common in pre-revenue biotech
- No revenue base, leaving the business entirely reliant on external capital and pipeline progress
- Large ongoing losses, including $-66.36M operating income and $-51.77M operating cash flow
- Weak profitability metrics, with ROE of -41.8% and ROA of -34.2%, indicating poor current capital efficiency
Key Metrics to Watch
- Monthly cash burn rate and cash runway extension timeline
- Clinical trial progress and regulatory pathway developments for lead candidates
- Quarterly operating cash flow trends toward profitability or stabilization
- Capital raise activity and dilution impact on equity
- Revenue generation timeline and commercial milestone achievements
- Quarterly operating cash burn relative to cash and equivalents
- Any transition from pre-revenue status to recurring collaboration, licensing, or product revenue
Alto Neuroscience, Inc. (ANRO) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 15.69x current ratio provides a solid financial cushion.
ANRO Profit Margin, ROE & Profitability Analysis
ANRO vs Healthcare Sector: How Alto Neuroscience, Inc. Compares
How Alto Neuroscience, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Alto Neuroscience, Inc. Stock Overvalued? ANRO Valuation Analysis 2026
Based on fundamental analysis, Alto Neuroscience, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Alto Neuroscience, Inc. Balance Sheet: ANRO Debt, Cash & Liquidity
ANRO Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Alto Neuroscience, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.50 indicates the company is currently unprofitable.
ANRO Revenue Growth, EPS Growth & YoY Performance
Alto Neuroscience, Inc. Dividends, Buybacks & Capital Allocation
ANRO SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Alto Neuroscience, Inc. (CIK: 0001999480)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ANRO
What is the AI rating for ANRO?
Alto Neuroscience, Inc. (ANRO) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 87% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ANRO's key strengths?
Claude: Strong liquidity position with $176.5M cash equivalents and 15.69x current ratio. Minimal debt burden with 0.11x debt-to-equity ratio providing financial flexibility. ChatGPT: Very strong liquidity, with a 15.69x current and quick ratio supported by $176.48M in cash. Low balance-sheet leverage, with debt/equity of just 0.11x and equity of $151.14M.
What are the risks of investing in ANRO?
Claude: Pre-revenue stage with no commercial products; entirely dependent on clinical trial success and regulatory approval. Substantial cash burn of $51.8M annually from operations will exhaust capital within ~6-7 years without revenue generation. ChatGPT: No revenue base, leaving the business entirely reliant on external capital and pipeline progress. Large ongoing losses, including $-66.36M operating income and $-51.77M operating cash flow.
What is ANRO's revenue and growth?
Alto Neuroscience, Inc. reported revenue of N/A.
Does ANRO pay dividends?
Alto Neuroscience, Inc. does not currently pay dividends.
Where can I find ANRO SEC filings?
Official SEC filings for Alto Neuroscience, Inc. (CIK: 0001999480) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ANRO's EPS?
Alto Neuroscience, Inc. has a diluted EPS of $-2.19.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ANRO a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Alto Neuroscience, Inc. has a SELL rating with 87% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ANRO stock overvalued or undervalued?
Valuation metrics for ANRO: ROE of -41.8% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ANRO stock in 2026?
Our dual AI analysis gives Alto Neuroscience, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ANRO's free cash flow?
Alto Neuroscience, Inc.'s operating cash flow is $-51.8M, with capital expenditures of $24.0K.
How does ANRO compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -41.8% (avg: 15%), current ratio 15.69 (avg: 2).